Evidence map›Paper›PMID 39502765›Full record

ArticleMedicine and pharmacy reports2024

Genetic and clinical factors influencing CF-associated liver disease: the impact of

Elena-Simona Moiceanu, Iustina Violeta Stan, Simona Elena Moşescu, Adina Chiş, Romana Vulturar, Daniel-Corneliu Leucuţa, Gabriela Viorela Niţescu, Maria Iacobescu, Elena Mădălina Petran, Dan Lucian Dumitraşcu

Abstract read
In one paragraph

Article in Medicine and pharmacy reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elena-Simona MoiceanuIuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Romania.
Iustina Violeta StanCarol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Simona Elena MoşescuDepartment of Pediatrics, Grigore Alexandrescu Clinical Emergency Hospital for Children, Bucharest, Romania.
Adina ChişDiscipline of Cell and Molecular Medicine, Department of Molecular Sciences, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Romana VulturarDiscipline of Cell and Molecular Medicine, Department of Molecular Sciences, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Daniel-Corneliu LeucuţaMedical Informatics and Biostatistics Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Gabriela Viorela NiţescuPediatric Poison Centre, Grigore Alexandrescu Clinical Emergency Hospital for Children, Bucharest, Romania.
Maria IacobescuInstitute of Medical Research and Life Sciences - MEDFUTURE, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Elena Mădălina PetranPediatric Poison Centre, Grigore Alexandrescu Clinical Emergency Hospital for Children, Bucharest, Romania.
Dan Lucian Dumitraşcu2nd Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatic disease represents a significant complication in children with cystic fibrosis (CF), yet its relationship with specific genetic factors, including CFTR (Cystic fibrosis transmembrane conductance regulator) mutations and SERPINA1 alleles, is not well understood. This study aims to clarify these associations within a Romanian pediatric CF population. Methods: In this cross-sectional, prospective study, we examined 71 children with CF, comparing those with hepatic disease (n=25) to those without (n=46). We collected comprehensive clinical, biochemical, and genetic data, focusing on CFTR genotypes and SERPINA1 alleles. Key outcomes included the prevalence of hepatic disease in relation to specific genotypes, fibrosis markers, and liver function tests. Results: The DF508/DF508 genotype was the most prevalent, occurring in 49% of the cohort. No significant associations were found between hepatic disease and specific CFTR genotypes or SERPINA1 alleles. However, children with hepatic disease exhibited significantly higher fibrosis scores (APRI and FIB-4), suggesting more advanced liver involvement. Additionally, a slight delay in CF diagnosis was observed in those with hepatic disease, though this difference did not reach statistical significance. Conclusion: This pioneering study in Romania underscores the complexity of hepatic disease in CF. While specific CFTR genotypes and SERPINA1 alleles were not significantly associated with hepatic complications, the findings emphasize the importance of early diagnosis and monitoring using fibrosis markers to identify children at risk for liver involvement.

Indexed as

CFTR genotypescystic fibrosishepatic diseaseSERPINA1 alleles

Identifiers

PMID39502765
PMCPMC11534388

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.